Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

about

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

Item

http://www.wikidata.org/entity/Q37298872

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Maximizing Benefits from Maint ...... ous Non-Small Cell Lung Cancer

@en

Maximizing Benefits from Maint ...... us Non-Small Cell Lung Cancer.

@nl

type

Item

label

Maximizing Benefits from Maint ...... ous Non-Small Cell Lung Cancer

@en

Maximizing Benefits from Maint ...... us Non-Small Cell Lung Cancer.

@nl

prefLabel

Maximizing Benefits from Maint ...... ous Non-Small Cell Lung Cancer

@en

Maximizing Benefits from Maint ...... us Non-Small Cell Lung Cancer.

@nl

P1476

Maximizing Benefits from Maint ...... ous Non-Small Cell Lung Cancer

@en

P2093

Feng-Ming Hsu

http://www.w3.org/2001/XMLSchema#string

Kuan-Yu Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.

Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.

Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors

SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer.

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.

Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

P304

474-480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000448804

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

James Chih-Hsin Yang

Chao-Chi Ho

Shao-Lun Lu

Jason Chia-Hsien Cheng

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27721771

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

5043363

http://www.w3.org/2001/XMLSchema#string